Whilst it is a shock to receive a diagnosis of cancer, in 2017, genomic diagnostic testing and screening techniques can now pinpoint treatments with a high probability of success.
Given that cancer medicines across the board have had a 75% failure rate, targeted treatments are giving positive therapeutic outcomes.
What’s more, Pharmacogenomics, enables us to look at the individual patient’s metabolic pathway efficiency to determine their response to a particular targeted treatment.
These three tools have raised the bar in what is called precision medicine.
When combined with the new breed of blood and tissue-based cancer vaccines, (not drug based immune vaccines) cancer patient outcomes are further enhanced